NASDAQ:MITI - Amgen Rockville Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileFinancialsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Designs and develops antibody-based drugs for treatment of cancer. The Company is a biotechnology company with a focus on the development of antibody-based products for cancer and inflammatory and autoimmune diseases. Micromet has established a drug development platform based on its BiTE technology, a drug format that leverages the cytotoxic potential of T cells. Receive MITI News and Ratings via Email Sign-up to receive the latest news and ratings for MITI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:MITI CUSIPN/A Webwww.micromet.com Phone+1-240-7521420 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 Amgen Rockville (NASDAQ:MITI) Frequently Asked Questions What is Amgen Rockville's stock symbol? Amgen Rockville trades on the NASDAQ under the ticker symbol "MITI." What is the consensus analysts' recommendation for Amgen Rockville? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen Rockville in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Has Amgen Rockville been receiving favorable news coverage? News headlines about MITI stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Amgen Rockville earned a news impact score of 0.09 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. How do I buy shares of Amgen Rockville? Shares of MITI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Amgen Rockville? Amgen Rockville's mailing address is 9201 Corporate Blvd Ste 400, ROCKVILLE, MD 20850-7209, United States. The biotechnology company can be reached via phone at +1-240-7521420. MarketBeat Community Rating for Amgen Rockville (NASDAQ MITI)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 61 (Vote Outperform)Underperform Votes: 58 (Vote Underperform)Total Votes: 119MarketBeat's community ratings are surveys of what our community members think about Amgen Rockville and other stocks. Vote "Outperform" if you believe MITI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MITI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?